Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-52862 for postherpetic neuralgia – randomized double-blind Phase II trial
2012-000399-41Phase 2Terminated
- Sponsor
- Esteve
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing E-52862 400 mg oral with Placebo oral (2 arms). Primary endpoint: Analgesic efficacy of E-52862. Started May 2012; status: terminated.
02
Drugs
E-52862
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2012-000399-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000399-41.